Optellum

This International Women's Day we're launching our Q&A with our investor Dr Tara Bishop of Black Opal Ventures, taking about the collision of healthcare and technology and what inspires her to invest in companies like Optellum.

Dr Tara Bishop: Inspiring investments at the collision of healthcare and technology Introducing Dr Tara Bishop, Black Opal Ventures, and the Optellum Virtual Nodule Clinic. Part of our celebration of International Women's Day 2024.

Optellum's vision is to redefine early intervention of lung cancer, enabling every clinician, in every hospital, to make the right decisions and give patients the best chance to fight back.

Lung cancer is the #1 cancer killer.

This we're launching our new video showing how Optellum can help clinicians with the only AI-based lung cancer clinical solution for early diagnosis.​​​​​​

The Optellum solution (animation) 2023 An animated video (no voiceover) which explains how Optellum is addressing the problem of late stage diagnosis for lung cancer.

Are you a digital communications professional based in the UK with experience in and ? Are you a creative communicator who enjoys using technology to reach varied audiences of customers, partners and influencers across multiple channels? Would you like to work with a talented and dedicated team to make a difference in the fight against lung cancer?

We are looking for a part time (22.5 to 30 hours per week) Digital Communications and Marketing Officer to join our fantastic team working with Head of Communications and Marketing Rhiannon Lassiter. You will be based in our Oxford office with hybrid working arrangements.

Please visit our careers page for details and send your CV and a covering letter to [email protected] explaining why you'd be a great fit for this role.

https://optellum.com/careers/

UK followers, please share with your own networks to help us find the new member of our team.

Careers - Optellum Optellum is a professional, expert, inclusive and international company with offices in the USA and in Oxford, UK.

https://optellum.com/2022/09/optellum-ai-lung-cancer-diagnosis-innovatorsecures-14m-series-a-funding-to-accelerate-expansion/

Optellum, AI Lung Cancer Diagnosis Innovator,Secures $14M Series A Funding to Accelerate Expansion - Optellum Oxford, 27 September 2022, 8am: Optellum, an Oxford-based medtech company that provides a breakthrough AI platform to diagnose and treat early-stage lung

Vanderbilt University Medical Center (VUMC) is the first hospital in Tennessee to introduce Optellum’s Virtual Nodule Clinic. The world-leading hospital was one of the first to conduct clinical trials of the software, under the leadership of the late Pierre Massion, which were published in the Journal of Respiratory and Critical Care Medicine in 2020.

The Vanderbilt Lung Institute, along with the Vanderbilt-Ingram Cancer Center, and the Lung Cancer Screening Program led by the Department of Radiology and Radiological Sciences, is now deploying the commercial software as part of its comprehensive care program to prevent, detect and treat lung cancer.

Lung cancer kills more people each year than any other cancer, and early detection is crucial to treatment and survival. Moreover, lung nodules are especially present in Tennessee due to a fungus called histoplasmosis. Most are not cancer, but it’s critical to detect the ones that are.

“That’s what this Optellum software will do. We are making a difference. Survival has improved. We think that has a lot to do with screening and early diagnosis.”
Otis Rickman, DO, Director of Interventional Pulmonology for the Vanderbilt Lung Institute.

Vanderbilt Lung Institute implements the Optellum Virtual Lung Nodule Clinic – Optellum Vanderbilt Lung Institute implements the Optellum Virtual Lung Nodule Clinic Post author:Rhiannon Lassiter Post published:January 4, 2022 Post category:Clinical / News and PR / Partners Vanderbilt University Hospital Medical Center (VUMC) is the first hospital in Tennessee to introduce Optellum’s ...

We’ve been in the news again this week as multiple outlets have covered our strategic collaboration with the Lung Cancer Initiative at Johnson & Johnson.

Lung health startup partners with Johnson & Johnson's lung cancer initiative A fast-growing lung health startup which aims to redefine early interception of lung cancer using AI decision support software has partnered with the Lung Cancer Initiative at Johnson & Johnson.

More good news for Optellum, grant funding and a partnership with 10 NHS hospitals for lung cancer prediction technology.

Optellum wins NHS funding - OCFI Optellum wins NHS funding for its AI decision support to detect early-stage lung cancer this week. Optellum was one of thirty-eight companies to receive the funding, which was announced by the Secretary of State for Health and Social Care.

PRESS RELEASE: Optellum receives FDA clearance for the world's first clinical decision support software for early lung cancer diagnosis.

PRESS RELEASE: Optellum Receives FDA Clearance for the World’s First AI-Powered Clinical Decision Support Software for Early Lung Cancer Diagnosis - Optellum Virtual Nodule Clinic empowers clinicians to make optimal clinical decisions in early-stage lung cancer diagnosis and is now commercially available in the United States. Oxford, United Kingdom – March 23, 2021 – Optellum, a lung health company aiming to redefine early diagnosis and treatment of ...

In recent months, three new appointments have expanded the Optellum team to grow commercial adoption of the Optellum Virtual Nodule Clinic software in the USA.

Optellum expands its commercial team in readiness for US sales - Optellum In recent months, three new appointments have expanded the Optellum team to grow commercial adoption of the Optellum Virtual Nodule Clinic software in the USA. Ryan Hennen (VP of US Sales) is a healthcare sales professional who brings twenty years’ experience consulting with large healthcare inte...